BioSpace News Archive

Investment validates recent progress and significant market opportunity in the oncology clinical trial space; will enable Massive Bio to scale up its pharmaceutical company and CRO services to meet rapidly increasing market demand and support its exponential customer growth using its AI-based technology solutions

Advanced Sterilization Products Unveils New-and-Improved STERRAD ® Sterility Guide (SSG) for Infection Prevention Professionals Online resource of reliable up-to-date STERRAD ® Systems sterilization information Both ASP and device manufacturers jointly perform a series of validations before a device can be added to the SSG, which is reassessed yearly to ensure quality and trust IRVINE, Calif.--( BUSINESS WIRE )-- Advanced Steriliza

Apollo Endosurgery, Inc. today announced that its management team will participate in two upcoming investor conference events during November 2020. November 17, 2020

Research agreement to investigate the feasibility of a proprietary biotechnology process for the industrial production of psilocybin API Psilocybin is designated by the FDA as a breakthrough therapy for severe depression

Companies have completed the EU regulatory application for marketing approval of avacopan Regulatory submission based on positive data from the pivotal P hase-III ADVOCATE trial of avacopan

Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that its mass cytometry technologies, including CyTOF ® , Imaging Mass Cytometry (IMC), and Maxpar ® Direct™, have been used in 113 National Clinical Trials listed in the clinicaltrials.gov database. This includes 94 ongoing and 19 completed clinical trials. Twenty-five

Spero Therapeutics, Inc. announced that on October 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020 after th

Truvian Sciences (“Truvian”), a healthcare company at the intersection of diagnostics and consumer technology, today unveiled the results of a first-of-its- kind research study validating the performance and accuracy of the Easy Check COVID-19 IgM/IgG™ antibody test

Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a co